Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6876629 | 0.85 | PARP1 (0.42) | PARP1PDPK1CSNK2A1CSNK2A2RAB9A | |
| SCHEMBL4612059 | 0.83 | SLC6A2 (0.43) | PARP1PDPK1CSNK2A1CSNK2A2RAB9A | |
| SCHEMBL6447653 | 0.83 | CSNK2A1 (0.41) | PARP1PDPK1CSNK2A1CSNK2A2RAB9A | |
| SCHEMBL6950307 | 0.83 | PARP1 (0.41) | PARP1PDPK1CSNK2A1CSNK2A2RAB9A | |
| SCHEMBL4612063 | 0.83 | PARP1 (0.41) | PARP1ALDH1A1HTT | |
| SCHEMBL13184288 | 0.83 | CSNK2A1 (0.41) | PARP1PDPK1CSNK2A1CSNK2A2RAB9A | |
| SCHEMBL6950313 | 0.83 | PARP1 (0.41) | PARP1PDPK1CSNK2A1CSNK2A2RAB9A | |
| SCHEMBL13156101 | 0.80 | PDPK1 (0.40) | PARP1PDPK1CSNK2A1CSNK2A2RAB9A | |
| SCHEMBL14347716 | 0.78 | ALDH1A1 (0.39) | PARP1PDPK1CSNK2A1CSNK2A2RAB9A | |
| SCHEMBL18948981 | 0.77 | BRD4 (0.46) | PARP1PDPK1HSD17B10HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240237380-A1 | LIGHT-EMITTING SUBSTRATE AND MANUFACTURING METHOD THEREOF, AND LIGHT-EMITTING APPARATUS | BOE TECHNOLOGY GROUP CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20230128137-A1 | BENZO FIVE-MEMBERED CYCLIC COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230128137-A1 | BENZO FIVE-MEMBERED CYCLIC COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-9758688-B2 | Composition for forming conductive film | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9704612-B2 | Composition of silver-conjugated compound composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-07-11 | — | — | US | disclosed |
| US-9536633-B2 | Metallic composite and composition thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-01-03 | — | — | US | disclosed |
| US-9527828-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9527828-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| EP-2218716-B1 | METHOD FOR AMPLIFYING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-20160322579-A1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-11-03 | — | — | US | disclosed |
| US-6225331-B1 | FOR THERAPY AND PROPHYLAXIS NASAL CONGESTION, OTITIS MEDIA, AND SINUSITIS, TREATING COUGH, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND/OR ASTHMA, BENIGN PROSTATIC HYPERTROPHY, CARDIOVASCULAR DISORDERS, GLAUCOMA, HYPEREMIA, CONJUNCTIVITIS | THE PROCTER & GAMBLE COMPANY | 2001-05-01 | — | — | US | disclosed |
| US-20010000345-A1 | Compounds such as (4,7-dimethylbenzimidazol-5-yl)guanidine; treating nasal congestion, otitis media, asthma, pain, migraine, gastrointestinal disorder, ulcer | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2001-04-19 | — | — | US | disclosed |
| EP-0944604-A1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023596-A1 | GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
| US-5691370-A | 5-(2-imidazolinylamino)benzimidazole compounds useful as alpha-2-adrenoceptor agonists | THE PROCTER & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
| CN-1137794-A | 5-(2-imidazolinylamino) benzimidazole derivatives, their preparation and their use as alpha-2 adrenoceptor agonists | PROCTER & GAMBLE (US) | 1996-12-11 | — | — | CN | disclosed |
| EP-0736022-A1 | 5-(2-IMIDAZOLINYLAMINO)BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5541210-A | ANALGESICS, ANTIINFLAMMATORY AGENTS, ANTIHISTAMINES OR COUGH MEDICINE | THE PROCTER & GAMBLE COMPANY (US) | 1996-07-30 | — | — | US | disclosed |
| US-5478858-A | Respiratory system disorders, gastrointestinal disorders | THE PROCTER & GAMBLE COMPANY (US) | 1995-12-26 | — | — | US | disclosed |
| WO-1995016685-A1 | 5-(2-IMIDAZOLINYLAMINO)BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010000345-A1 | Compounds such as (4,7-dimethylbenzimidazol-5-yl)guanidine; treating nasal congestion, otitis media, asthma, pain, migraine, gastrointestinal disorder, ulcer | ADRB2, ADRA2C, ADRA2B | PARP1 3103/4885PDPK1 3528/4885CSNK2A1 3107/4885 |
| US-20230128137-A1 | BENZO FIVE-MEMBERED CYCLIC COMPOUND | BCL2, BAX, BCL2L1 | PARP1 1523/4885PDPK1 1711/4885CSNK2A1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.